- Home
- AXL vs EYPT Comparison
AXL vs EYPT Comparison
Compare AXL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXL | EYPT |
|---|---|---|
| Founded | 1994 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.5M | 1.5B |
| IPO Year | 1999 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AXL | EYPT |
|---|---|---|
| Price | $6.40 | $16.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $7.06 | ★ $29.60 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $5,833,600,000.00 | $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.71 | N/A |
| P/E Ratio | $18.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.00 | $3.91 |
| 52 Week High | $6.90 | $19.11 |
Technical Indicators
Market Signals| Indicator | AXL | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 60.28 |
| Support Level | $5.99 | $15.97 |
| Resistance Level | $6.68 | $19.11 |
| Average True Range (ATR) | 0.22 | 0.96 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 60.76 | 46.36 |
Price Performance
Historical ComparisonAbout AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.